• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market by Geography
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Drug Class
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• 4 Historic Market Size
o 4.1 Global idiopathic pulmonary fibrosis market 2017 – 2021
o Exhibit 18: Historic Market Size – Data Table on Global idiopathic pulmonary fibrosis market 2017 – 2021 ($ million)
o 4.2 Route of Administration Segment Analysis 2017 – 2021
o Exhibit 19: Historic Market Size – Route of Administration Segment 2017 – 2021 ($ million)
o 4.3 Drug Class Segment Analysis 2017 – 2021
o Exhibit 20: Historic Market Size – Drug Class Segment 2017 – 2021 ($ million)
o 4.4 Geography Segment Analysis 2017 – 2021
o Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
o 4.5 Country Segment Analysis 2017 – 2021
o Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
• 6 Market Segmentation by Route of Administration
o 6.1 Market segments
o Exhibit 30: Chart on Route of Administration – Market share 2022-2027 (%)
o Exhibit 31: Data Table on Route of Administration – Market share 2022-2027 (%)
o 6.2 Comparison by Route of Administration
o Exhibit 32: Chart on Comparison by Route of Administration
o Exhibit 33: Data Table on Comparison by Route of Administration
o 6.3 Oral – Market size and forecast 2022-2027
o Exhibit 34: Chart on Oral – Market size and forecast 2022-2027 ($ million)
o Exhibit 35: Data Table on Oral – Market size and forecast 2022-2027 ($ million)
o Exhibit 36: Chart on Oral – Year-over-year growth 2022-2027 (%)
o Exhibit 37: Data Table on Oral – Year-over-year growth 2022-2027 (%)
o 6.4 Parenteral – Market size and forecast 2022-2027
o Exhibit 38: Chart on Parenteral – Market size and forecast 2022-2027 ($ million)
o Exhibit 39: Data Table on Parenteral – Market size and forecast 2022-2027 ($ million)
o Exhibit 40: Chart on Parenteral – Year-over-year growth 2022-2027 (%)
o Exhibit 41: Data Table on Parenteral – Year-over-year growth 2022-2027 (%)
o 6.5 Market opportunity by Route of Administration
o Exhibit 42: Market opportunity by Route of Administration ($ million)
o Exhibit 43: Data Table on Market opportunity by Route of Administration ($ million)
• 7 Market Segmentation by Drug Class
o 7.1 Market segments
o Exhibit 44: Chart on Drug Class – Market share 2022-2027 (%)
o Exhibit 45: Data Table on Drug Class – Market share 2022-2027 (%)
o 7.2 Comparison by Drug Class
o Exhibit 46: Chart on Comparison by Drug Class
o Exhibit 47: Data Table on Comparison by Drug Class
o 7.3 Systemic corticosteroids – Market size and forecast 2022-2027
o Exhibit 48: Chart on Systemic corticosteroids – Market size and forecast 2022-2027 ($ million)
o Exhibit 49: Data Table on Systemic corticosteroids – Market size and forecast 2022-2027 ($ million)
o Exhibit 50: Chart on Systemic corticosteroids – Year-over-year growth 2022-2027 (%)
o Exhibit 51: Data Table on Systemic corticosteroids – Year-over-year growth 2022-2027 (%)
o 7.4 Immunosuppressants – Market size and forecast 2022-2027
o Exhibit 52: Chart on Immunosuppressants – Market size and forecast 2022-2027 ($ million)
o Exhibit 53: Data Table on Immunosuppressants – Market size and forecast 2022-2027 ($ million)
o Exhibit 54: Chart on Immunosuppressants – Year-over-year growth 2022-2027 (%)
o Exhibit 55: Data Table on Immunosuppressants – Year-over-year growth 2022-2027 (%)
o 7.5 Tyrosine kinase inhibitors – Market size and forecast 2022-2027
o Exhibit 56: Chart on Tyrosine kinase inhibitors – Market size and forecast 2022-2027 ($ million)
o Exhibit 57: Data Table on Tyrosine kinase inhibitors – Market size and forecast 2022-2027 ($ million)
o Exhibit 58: Chart on Tyrosine kinase inhibitors – Year-over-year growth 2022-2027 (%)
o Exhibit 59: Data Table on Tyrosine kinase inhibitors – Year-over-year growth 2022-2027 (%)
o 7.6 Anti-fibrotic agents – Market size and forecast 2022-2027
o Exhibit 60: Chart on Anti-fibrotic agents – Market size and forecast 2022-2027 ($ million)
o Exhibit 61: Data Table on Anti-fibrotic agents – Market size and forecast 2022-2027 ($ million)
o Exhibit 62: Chart on Anti-fibrotic agents – Year-over-year growth 2022-2027 (%)
o Exhibit 63: Data Table on Anti-fibrotic agents – Year-over-year growth 2022-2027 (%)
o 7.7 Market opportunity by Drug Class
o Exhibit 64: Market opportunity by Drug Class ($ million)
o Exhibit 65: Data Table on Market opportunity by Drug Class ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 67: Chart on Market share by geography 2022-2027 (%)
o Exhibit 68: Data Table on Market share by geography 2022-2027 (%)
o 9.2 Geographic comparison
o Exhibit 69: Chart on Geographic comparison
o Exhibit 70: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2022-2027
o Exhibit 71: Chart on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 72: Data Table on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 73: Chart on North America – Year-over-year growth 2022-2027 (%)
o Exhibit 74: Data Table on North America – Year-over-year growth 2022-2027 (%)
o 9.4 Europe – Market size and forecast 2022-2027
o Exhibit 75: Chart on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 76: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 77: Chart on Europe – Year-over-year growth 2022-2027 (%)
o Exhibit 78: Data Table on Europe – Year-over-year growth 2022-2027 (%)
o 9.5 Asia – Market size and forecast 2022-2027
o Exhibit 79: Chart on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 80: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 81: Chart on Asia – Year-over-year growth 2022-2027 (%)
o Exhibit 82: Data Table on Asia – Year-over-year growth 2022-2027 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
o Exhibit 83: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 84: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 85: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o Exhibit 86: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o 9.7 US – Market size and forecast 2022-2027
o Exhibit 87: Chart on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 88: Data Table on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 89: Chart on US – Year-over-year growth 2022-2027 (%)
o Exhibit 90: Data Table on US – Year-over-year growth 2022-2027 (%)
o 9.8 China – Market size and forecast 2022-2027
o Exhibit 91: Chart on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 92: Data Table on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 93: Chart on China – Year-over-year growth 2022-2027 (%)
o Exhibit 94: Data Table on China – Year-over-year growth 2022-2027 (%)
o 9.9 Japan – Market size and forecast 2022-2027
o Exhibit 95: Chart on Japan – Market size and forecast 2022-2027 ($ million)
o Exhibit 96: Data Table on Japan – Market size and forecast 2022-2027 ($ million)
o Exhibit 97: Chart on Japan – Year-over-year growth 2022-2027 (%)
o Exhibit 98: Data Table on Japan – Year-over-year growth 2022-2027 (%)
o 9.10 Germany – Market size and forecast 2022-2027
o Exhibit 99: Chart on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 100: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 101: Chart on Germany – Year-over-year growth 2022-2027 (%)
o Exhibit 102: Data Table on Germany – Year-over-year growth 2022-2027 (%)
o 9.11 UK – Market size and forecast 2022-2027
o Exhibit 103: Chart on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 104: Data Table on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 105: Chart on UK – Year-over-year growth 2022-2027 (%)
o Exhibit 106: Data Table on UK – Year-over-year growth 2022-2027 (%)
o 9.12 Market opportunity by geography
o Exhibit 107: Market opportunity by geography ($ million)
o Exhibit 108: Data Tables on Market opportunity by geography ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 109: Impact of drivers and challenges in 2022 and 2027
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 111: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 112: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 113: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 114: Matrix on vendor position and classification
o 12.3 AstraZeneca Plc
o Exhibit 115: AstraZeneca Plc – Overview
o Exhibit 116: AstraZeneca Plc – Product / Service
o Exhibit 117: AstraZeneca Plc – Key news
o Exhibit 118: AstraZeneca Plc – Key offerings
o 12.4 Boehringer Ingelheim International GmbH
o Exhibit 119: Boehringer Ingelheim International GmbH – Overview
o Exhibit 120: Boehringer Ingelheim International GmbH – Business segments
o Exhibit 121: Boehringer Ingelheim International GmbH – Key news
o Exhibit 122: Boehringer Ingelheim International GmbH – Key offerings
o Exhibit 123: Boehringer Ingelheim International GmbH – Segment focus
o 12.5 Bristol Myers Squibb Co.
o Exhibit 124: Bristol Myers Squibb Co. – Overview
o Exhibit 125: Bristol Myers Squibb Co. – Product / Service
o Exhibit 126: Bristol Myers Squibb Co. – Key news
o Exhibit 127: Bristol Myers Squibb Co. – Key offerings
o 12.6 Cipla Ltd.
o Exhibit 128: Cipla Ltd. – Overview
o Exhibit 129: Cipla Ltd. – Business segments
o Exhibit 130: Cipla Ltd. – Key news
o Exhibit 131: Cipla Ltd. – Key offerings
o Exhibit 132: Cipla Ltd. – Segment focus
o 12.7 F. Hoffmann La Roche Ltd.
o Exhibit 133: F. Hoffmann La Roche Ltd. – Overview
o Exhibit 134: F. Hoffmann La Roche Ltd. – Business segments
o Exhibit 135: F. Hoffmann La Roche Ltd. – Key news
o Exhibit 136: F. Hoffmann La Roche Ltd. – Key offerings
o Exhibit 137: F. Hoffmann La Roche Ltd. – Segment focus
o 12.8 FibroGen Inc.
o Exhibit 138: FibroGen Inc. – Overview
o Exhibit 139: FibroGen Inc. – Product / Service
o Exhibit 140: FibroGen Inc. – Key offerings
o 12.9 Galapagos NV
o Exhibit 141: Galapagos NV – Overview
o Exhibit 142: Galapagos NV – Product / Service
o Exhibit 143: Galapagos NV – Key offerings
o 12.10 GNI Group Ltd.
o Exhibit 144: GNI Group Ltd. – Overview
o Exhibit 145: GNI Group Ltd. – Product / Service
o Exhibit 146: GNI Group Ltd. – Key offerings
o 12.11 Horizon Therapeutics Plc
o Exhibit 147: Horizon Therapeutics Plc – Overview
o Exhibit 148: Horizon Therapeutics Plc – Business segments
o Exhibit 149: Horizon Therapeutics Plc – Key news
o Exhibit 150: Horizon Therapeutics Plc – Key offerings
o Exhibit 151: Horizon Therapeutics Plc – Segment focus
o 12.12 Jubilant Pharmova Ltd.
o Exhibit 152: Jubilant Pharmova Ltd. – Overview
o Exhibit 153: Jubilant Pharmova Ltd. – Business segments
o Exhibit 154: Jubilant Pharmova Ltd. – Key news
o Exhibit 155: Jubilant Pharmova Ltd. – Key offerings
o Exhibit 156: Jubilant Pharmova Ltd. – Segment focus
o 12.13 Liminal BioSciences Inc.
o Exhibit 157: Liminal BioSciences Inc. – Overview
o Exhibit 158: Liminal BioSciences Inc. – Product / Service
o Exhibit 159: Liminal BioSciences Inc. – Key offerings
o 12.14 MediciNova Inc.
o Exhibit 160: MediciNova Inc. – Overview
o Exhibit 161: MediciNova Inc. – Product / Service
o Exhibit 162: MediciNova Inc. – Key offerings
o 12.15 Novartis AG
o Exhibit 163: Novartis AG – Overview
o Exhibit 164: Novartis AG – Business segments
o Exhibit 165: Novartis AG – Key offerings
o Exhibit 166: Novartis AG – Segment focus
o 12.16 Shionogi and Co. Ltd.
o Exhibit 167: Shionogi and Co. Ltd. – Overview
o Exhibit 168: Shionogi and Co. Ltd. – Product / Service
o Exhibit 169: Shionogi and Co. Ltd. – Key offerings
o 12.17 United Therapeutics Corp.
o Exhibit 170: United Therapeutics Corp. – Overview
o Exhibit 171: United Therapeutics Corp. – Product / Service
o Exhibit 172: United Therapeutics Corp. – Key offerings
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 173: Inclusions checklist
o Exhibit 174: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 175: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 176: Research methodology
o Exhibit 177: Validation techniques employed for market sizing
o Exhibit 178: Information sources
o 13.5 List of abbreviations
o Exhibit 179: List of abbreviations

Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market by Geography
Exhibits5: Executive Summary – Chart on Market Segmentation by Route of Administration
Exhibits6: Executive Summary – Chart on Market Segmentation by Drug Class
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size – Data Table on Global idiopathic pulmonary fibrosis market 2017 – 2021 ($ million)
Exhibits19: Historic Market Size – Route of Administration Segment 2017 – 2021 ($ million)
Exhibits20: Historic Market Size – Drug Class Segment 2017 – 2021 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
Exhibits22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
Exhibits23: Five forces analysis – Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants – Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes – Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry – Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition – Five forces 2022 and 2027
Exhibits30: Chart on Route of Administration – Market share 2022-2027 (%)
Exhibits31: Data Table on Route of Administration – Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Route of Administration
Exhibits33: Data Table on Comparison by Route of Administration
Exhibits34: Chart on Oral – Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on Oral – Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on Oral – Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on Oral – Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on Parenteral – Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on Parenteral – Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on Parenteral – Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on Parenteral – Year-over-year growth 2022-2027 (%)
Exhibits42: Market opportunity by Route of Administration ($ million)
Exhibits43: Data Table on Market opportunity by Route of Administration ($ million)
Exhibits44: Chart on Drug Class – Market share 2022-2027 (%)
Exhibits45: Data Table on Drug Class – Market share 2022-2027 (%)
Exhibits46: Chart on Comparison by Drug Class
Exhibits47: Data Table on Comparison by Drug Class
Exhibits48: Chart on Systemic corticosteroids – Market size and forecast 2022-2027 ($ million)
Exhibits49: Data Table on Systemic corticosteroids – Market size and forecast 2022-2027 ($ million)
Exhibits50: Chart on Systemic corticosteroids – Year-over-year growth 2022-2027 (%)
Exhibits51: Data Table on Systemic corticosteroids – Year-over-year growth 2022-2027 (%)
Exhibits52: Chart on Immunosuppressants – Market size and forecast 2022-2027 ($ million)
Exhibits53: Data Table on Immunosuppressants – Market size and forecast 2022-2027 ($ million)
Exhibits54: Chart on Immunosuppressants – Year-over-year growth 2022-2027 (%)
Exhibits55: Data Table on Immunosuppressants – Year-over-year growth 2022-2027 (%)
Exhibits56: Chart on Tyrosine kinase inhibitors – Market size and forecast 2022-2027 ($ million)
Exhibits57: Data Table on Tyrosine kinase inhibitors – Market size and forecast 2022-2027 ($ million)
Exhibits58: Chart on Tyrosine kinase inhibitors – Year-over-year growth 2022-2027 (%)
Exhibits59: Data Table on Tyrosine kinase inhibitors – Year-over-year growth 2022-2027 (%)
Exhibits60: Chart on Anti-fibrotic agents – Market size and forecast 2022-2027 ($ million)
Exhibits61: Data Table on Anti-fibrotic agents – Market size and forecast 2022-2027 ($ million)
Exhibits62: Chart on Anti-fibrotic agents – Year-over-year growth 2022-2027 (%)
Exhibits63: Data Table on Anti-fibrotic agents – Year-over-year growth 2022-2027 (%)
Exhibits64: Market opportunity by Drug Class ($ million)
Exhibits65: Data Table on Market opportunity by Drug Class ($ million)
Exhibits66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits67: Chart on Market share by geography 2022-2027 (%)
Exhibits68: Data Table on Market share by geography 2022-2027 (%)
Exhibits69: Chart on Geographic comparison
Exhibits70: Data Table on Geographic comparison
Exhibits71: Chart on North America – Market size and forecast 2022-2027 ($ million)
Exhibits72: Data Table on North America – Market size and forecast 2022-2027 ($ million)
Exhibits73: Chart on North America – Year-over-year growth 2022-2027 (%)
Exhibits74: Data Table on North America – Year-over-year growth 2022-2027 (%)
Exhibits75: Chart on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits76: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits77: Chart on Europe – Year-over-year growth 2022-2027 (%)
Exhibits78: Data Table on Europe – Year-over-year growth 2022-2027 (%)
Exhibits79: Chart on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits80: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits81: Chart on Asia – Year-over-year growth 2022-2027 (%)
Exhibits82: Data Table on Asia – Year-over-year growth 2022-2027 (%)
Exhibits83: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits84: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits85: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits86: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits87: Chart on US – Market size and forecast 2022-2027 ($ million)
Exhibits88: Data Table on US – Market size and forecast 2022-2027 ($ million)
Exhibits89: Chart on US – Year-over-year growth 2022-2027 (%)
Exhibits90: Data Table on US – Year-over-year growth 2022-2027 (%)
Exhibits91: Chart on China – Market size and forecast 2022-2027 ($ million)
Exhibits92: Data Table on China – Market size and forecast 2022-2027 ($ million)
Exhibits93: Chart on China – Year-over-year growth 2022-2027 (%)
Exhibits94: Data Table on China – Year-over-year growth 2022-2027 (%)
Exhibits95: Chart on Japan – Market size and forecast 2022-2027 ($ million)
Exhibits96: Data Table on Japan – Market size and forecast 2022-2027 ($ million)
Exhibits97: Chart on Japan – Year-over-year growth 2022-2027 (%)
Exhibits98: Data Table on Japan – Year-over-year growth 2022-2027 (%)
Exhibits99: Chart on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits100: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits101: Chart on Germany – Year-over-year growth 2022-2027 (%)
Exhibits102: Data Table on Germany – Year-over-year growth 2022-2027 (%)
Exhibits103: Chart on UK – Market size and forecast 2022-2027 ($ million)
Exhibits104: Data Table on UK – Market size and forecast 2022-2027 ($ million)
Exhibits105: Chart on UK – Year-over-year growth 2022-2027 (%)
Exhibits106: Data Table on UK – Year-over-year growth 2022-2027 (%)
Exhibits107: Market opportunity by geography ($ million)
Exhibits108: Data Tables on Market opportunity by geography ($ million)
Exhibits109: Impact of drivers and challenges in 2022 and 2027
Exhibits110: Overview on Criticality of inputs and Factors of differentiation
Exhibits111: Overview on factors of disruption
Exhibits112: Impact of key risks on business
Exhibits113: Vendors covered
Exhibits114: Matrix on vendor position and classification
Exhibits115: AstraZeneca Plc – Overview
Exhibits116: AstraZeneca Plc – Product / Service
Exhibits117: AstraZeneca Plc – Key news
Exhibits118: AstraZeneca Plc – Key offerings
Exhibits119: Boehringer Ingelheim International GmbH – Overview
Exhibits120: Boehringer Ingelheim International GmbH – Business segments
Exhibits121: Boehringer Ingelheim International GmbH – Key news
Exhibits122: Boehringer Ingelheim International GmbH – Key offerings
Exhibits123: Boehringer Ingelheim International GmbH – Segment focus
Exhibits124: Bristol Myers Squibb Co. – Overview
Exhibits125: Bristol Myers Squibb Co. – Product / Service
Exhibits126: Bristol Myers Squibb Co. – Key news
Exhibits127: Bristol Myers Squibb Co. – Key offerings
Exhibits128: Cipla Ltd. – Overview
Exhibits129: Cipla Ltd. – Business segments
Exhibits130: Cipla Ltd. – Key news
Exhibits131: Cipla Ltd. – Key offerings
Exhibits132: Cipla Ltd. – Segment focus
Exhibits133: F. Hoffmann La Roche Ltd. – Overview
Exhibits134: F. Hoffmann La Roche Ltd. – Business segments
Exhibits135: F. Hoffmann La Roche Ltd. – Key news
Exhibits136: F. Hoffmann La Roche Ltd. – Key offerings
Exhibits137: F. Hoffmann La Roche Ltd. – Segment focus
Exhibits138: FibroGen Inc. – Overview
Exhibits139: FibroGen Inc. – Product / Service
Exhibits140: FibroGen Inc. – Key offerings
Exhibits141: Galapagos NV – Overview
Exhibits142: Galapagos NV – Product / Service
Exhibits143: Galapagos NV – Key offerings
Exhibits144: GNI Group Ltd. – Overview
Exhibits145: GNI Group Ltd. – Product / Service
Exhibits146: GNI Group Ltd. – Key offerings
Exhibits147: Horizon Therapeutics Plc – Overview
Exhibits148: Horizon Therapeutics Plc – Business segments
Exhibits149: Horizon Therapeutics Plc – Key news
Exhibits150: Horizon Therapeutics Plc – Key offerings
Exhibits151: Horizon Therapeutics Plc – Segment focus
Exhibits152: Jubilant Pharmova Ltd. – Overview
Exhibits153: Jubilant Pharmova Ltd. – Business segments
Exhibits154: Jubilant Pharmova Ltd. – Key news
Exhibits155: Jubilant Pharmova Ltd. – Key offerings
Exhibits156: Jubilant Pharmova Ltd. – Segment focus
Exhibits157: Liminal BioSciences Inc. – Overview
Exhibits158: Liminal BioSciences Inc. – Product / Service
Exhibits159: Liminal BioSciences Inc. – Key offerings
Exhibits160: MediciNova Inc. – Overview
Exhibits161: MediciNova Inc. – Product / Service
Exhibits162: MediciNova Inc. – Key offerings
Exhibits163: Novartis AG – Overview
Exhibits164: Novartis AG – Business segments
Exhibits165: Novartis AG – Key offerings
Exhibits166: Novartis AG – Segment focus
Exhibits167: Shionogi and Co. Ltd. – Overview
Exhibits168: Shionogi and Co. Ltd. – Product / Service
Exhibits169: Shionogi and Co. Ltd. – Key offerings
Exhibits170: United Therapeutics Corp. – Overview
Exhibits171: United Therapeutics Corp. – Product / Service
Exhibits172: United Therapeutics Corp. – Key offerings
Exhibits173: Inclusions checklist
Exhibits174: Exclusions checklist
Exhibits175: Currency conversion rates for US$
Exhibits176: Research methodology
Exhibits177: Validation techniques employed for market sizing
Exhibits178: Information sources
Exhibits179: List of abbreviations